Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the stock, ...
pharmaphorum2d
The biggest challenges facing rare disease pharma – and how the industry can tackle them
with a drug now in Phase 2 to treat the fibrosis element of Alström Syndrome as a result of such interaction. GlobalData’s analysis ultimately says that orphan drugs face an “uphill battle ...